CINECA IRIS Institutional Research Information System

MORETTO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.870
AS - Asia 1.263
EU - Europa 858
SA - Sud America 249
Continente sconosciuto - Info sul continente non disponibili 109
AF - Africa 72
OC - Oceania 2
Totale 5.423
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.764
SG - Singapore 431
CN - Cina 311
IT - Italia 269
HK - Hong Kong 207
BR - Brasile 195
VN - Vietnam 145
SE - Svezia 121
GB - Regno Unito 99
DE - Germania 96
CA - Canada 65
FR - Francia 65
BG - Bulgaria 64
IN - India 37
RU - Federazione Russa 36
FI - Finlandia 31
JP - Giappone 28
CI - Costa d'Avorio 26
AR - Argentina 23
BD - Bangladesh 19
TR - Turchia 19
PL - Polonia 17
KR - Corea 14
ZA - Sudafrica 14
AT - Austria 10
ES - Italia 10
NG - Nigeria 10
SN - Senegal 10
ID - Indonesia 9
MX - Messico 9
IQ - Iraq 8
NL - Olanda 8
UA - Ucraina 8
EC - Ecuador 7
JM - Giamaica 7
SA - Arabia Saudita 7
CO - Colombia 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
HN - Honduras 5
IE - Irlanda 5
PK - Pakistan 5
VE - Venezuela 5
CL - Cile 4
MA - Marocco 4
CH - Svizzera 3
NI - Nicaragua 3
NP - Nepal 3
PE - Perù 3
PS - Palestinian Territory 3
PY - Paraguay 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AU - Australia 2
BO - Bolivia 2
DZ - Algeria 2
GT - Guatemala 2
LT - Lituania 2
MY - Malesia 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
UY - Uruguay 2
AG - Antigua e Barbuda 1
AL - Albania 1
AW - Aruba 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BS - Bahamas 1
BW - Botswana 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
NO - Norvegia 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 5.314
Salva come PNG Salva come JPEG
Città #
Ashburn 354
Singapore 237
Hong Kong 202
San Jose 202
Dallas 200
Santa Clara 184
Fairfield 177
Woodbridge 153
Chandler 111
Shanghai 97
Seattle 86
Houston 85
Cambridge 75
Wilmington 71
New York 65
Sofia 63
Ann Arbor 58
Council Bluffs 58
Los Angeles 57
Beijing 50
Boardman 47
London 43
Florence 42
Munich 38
Ho Chi Minh City 33
Princeton 30
Pisa 29
Lawrence 28
Milan 28
Abidjan 26
Tokyo 25
Lauterbourg 22
Ottawa 22
Hanoi 21
Hefei 21
São Paulo 20
Serra 19
Buffalo 18
Frankfurt am Main 18
Medford 18
Cascina 17
Redondo Beach 17
Dearborn 16
Warsaw 16
Bremen 15
Des Moines 14
Istanbul 14
Ogden 14
Seoul 14
Turku 14
Lancaster 13
Chicago 11
Rio de Janeiro 11
Toronto 11
Dakar 10
Düsseldorf 10
Helsinki 10
Lagos 10
Montreal 10
Orem 10
Seacroft 10
Vienna 9
Washington 9
Da Nang 8
Phoenix 8
Verona 8
Brooklyn 7
Columbus 7
Denver 7
Dong Ket 7
Fuzhou 7
Nanjing 7
Rome 7
San Diego 7
Curitiba 6
Fortaleza 6
Johannesburg 6
Redwood City 6
Chennai 5
Dublin 5
Guarulhos 5
Haiphong 5
Nuremberg 5
Poplar 5
Turin 5
Atlanta 4
Baghdad 4
Charlotte 4
Genoa 4
Mumbai 4
Paris 4
Piscataway 4
San José 4
Shenyang 4
Asunción 3
Belo Horizonte 3
Boston 3
Brasília 3
Bromsgrove 3
Cincinnati 3
Totale 3.611
Salva come PNG Salva come JPEG
Nome #
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 203
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 191
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 187
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 184
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 184
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 178
The landscape of alterations in DNA damage response pathways in colorectal cancer 177
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 176
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 175
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 174
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 174
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 174
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 174
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 165
A still missing piece of the FIRE-3 puzzle 160
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 158
Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer 154
BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases 150
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 146
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 142
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 142
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 142
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 141
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 134
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 130
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients 127
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 127
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 126
Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection 125
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 124
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 114
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 113
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 110
null 85
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 70
null 65
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment 54
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 41
Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorithm 27
Totale 5.423
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.354
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022229 0 0 0 0 46 53 2 9 13 22 15 69
2022/2023417 42 68 38 29 41 44 7 30 60 0 55 3
2023/2024337 23 25 49 21 48 47 26 10 10 10 33 35
2024/20251.188 12 35 30 58 107 146 118 52 110 138 115 267
2025/20261.591 96 190 231 205 147 99 196 73 92 146 90 26
2026/2027618 67 82 208 238 23 0 0 0 0 0 0 0
Totale 5.423